首页> 外文期刊>Der Pharmacia Lettre >Diclofenac sodium pellets for flexible pediatric drug dosing: Preparation, characterization and evaluation
【24h】

Diclofenac sodium pellets for flexible pediatric drug dosing: Preparation, characterization and evaluation

机译:双氯芬酸钠微丸用于小儿药物剂量的制备,表征和评估

获取原文
           

摘要

The objective of the current investigation was to formulate Eudragit RS100 based sustained release pellets, containing Diclofenac sodium intended for flexible dosing in pediatric patients. Diclofenac sodium is a type II antiinflamatory agent. Pellets in the form of microspheres were prepared by O/O emulsion solvent evaporation method with different stabilizer concentrations and at different speeds of emulsification while maintaining constant amounts of Diclofenac sodium. Span 80 was used as the stabilizer. Drug excipient compatibility study was performed prior to formulation development and only compatible excipients were used in the fabrication of microspheres. Prepared microsphere formulations were characterized for percentage yield, particle size analysis, entrapment efficiency, invitro release behavior, differential scanning colorimetry (DSC), scanning electron microscopy (SEM), in vivo drug release and in vitro in vivo correlation (IVIVC). SEM studies showed that the microspheres were spherical with rough surface morphology. The drug loaded microspheres showed 50-80% entrapment efficiency. The invitro release profile showed a slow and steady release pattern for Diclofenac sodium. A 100% Diclofenac sodium was released within a period of 12 hrs during this time. The drug release was found to follow diffusion controlled mechanism. The n value of Korsmeyer Peppas equation indicated non Fickian type of diffusion. DSC results indicated that the physical state of the drug was changed upon fabrication. In rats, the pellets released the drug for over a period of 12 hrs after oral administration. A 100% IVIVC was achieved with the optimized formulation. As a result of these experiments, it was concluded that, novel sustained release oral pellets comprising of diclofenac sodium were successfully prepared using eudragit RS100 as the polymer and using emulsion solvent evaluation method.
机译:当前研究的目的是配制基于Eudragit RS100的缓释微丸,其中含有双氯芬酸钠,用于小儿患者的灵活给药。双氯芬酸钠是II型抗炎药。通过O / O乳液溶剂蒸发法,以不同的稳定剂浓度和不同的乳化速度,同时保持恒定量的双氯芬酸钠来制备微球形式的粒料。跨度80被用作稳定器。药物赋形剂的相容性研究是在制剂开发之前进行的,只有相容的赋形剂用于微球的制备。制备的微球制剂的特征在于百分产率,粒度分析,包封效率,体外释放行为,差示扫描比色法(DSC),扫描电子显微镜(SEM),体内药物释放和体外体内相关性(IVIVC)。 SEM研究表明,微球是球形的,具有粗糙的表面形态。载药微球显示出50-80%的包封率。体外释放曲线显示双氯芬酸钠的缓慢且稳定的释放模式。在这段时间内,在12小时内释放了100%双氯芬酸钠。发现药物释放遵循扩散控制机制。 Korsmeyer Peppas方程的n值表示非Fickian扩散类型。 DSC结果表明该药物的物理状态在制造时改变。在大鼠中,小丸在口服后12个小时内释放出药物。优化配方可实现100%IVIVC。作为这些实验的结果,得出的结论是,使用eudragit RS100作为聚合物并使用乳液溶剂评价方法成功地制备了包含双氯芬酸钠的新型缓释口服丸剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号